China Pilots Active Monitoring of Pneumonia with Unknown Causes, Eyes Nationwide Implementation

China Strengthens Infectious Disease Monitoring with Pilot Program and Technological Advancements

China's National Disease Control and Prevention Administration (NDCPA) has announced a pilot program to actively monitor cases of pneumonia with unknown causes. This program aims to provide early warnings and facilitate a swift response to potential outbreaks. The NDCPA also outlined plans for a nationwide implementation of the program following necessary refinements.

The NDCPA is actively developing a reporting directory for pathogenic microorganisms to clarify laboratory reporting procedures and processes for verification and handling by disease control agencies. This directory will involve laboratories from various institutions, including disease control agencies, medical and health institutions, third-party testing agencies, universities, research institutes, and other relevant departments.

To enhance the sensitivity and accuracy of its infectious disease monitoring systems, China has expanded its disease monitoring channels. The NDCPA has optimized the network reporting system for infectious diseases to monitor acute respiratory infectious diseases, including COVID-19 and influenza, at 1,041 sentinel hospitals across all cities and representative counties. Additionally, some of these sentinel hospitals have been selected to monitor various common respiratory pathogens. The Chinese Center for Disease Control and Prevention releases multi-pathogen monitoring results to the public on a weekly basis and provides health advisories.

China has also established regional infectious disease monitoring, early warning, and emergency command information platforms in some regions, such as Beijing and East China's Zhejiang Province. To ensure effective data integration related to infectious diseases between medical institutions and disease control agencies, the national intelligent monitoring and early warning software for infectious diseases has been deployed in public medical institutions at the secondary level and above across the country. As of now, the integration deployment rate has reached 71 percent.

Furthermore, new technologies such as big data and artificial intelligence are being utilized to enhance the automatic analysis and early warning capabilities of infectious disease data. These advancements will further strengthen China's ability to detect and respond to emerging infectious diseases.